Former diabetes drug may help in the treatment of breast cancer, study shows

NewsGuard 100/100 Score

Findings from a new study led by Yale Cancer Center show the small molecule inhibitor drug, PF05175157, originally developed to treat diabetes by Pfizer, may help in the treatment of breast cancer. The findings were reported today at the 2021 San Antonio Breast Cancer Symposium in San Antonio, Texas.

Our research shows the preclinical, anti-cancer activity using PF05175157 may lead us to bring this drug back into the clinic to help treat patients with breast cancer. More studies are needed, but our initial data looks very promising."

Julia Foldi, MD, PhD, lead study author, clinical fellow, Yale Cancer Center and Smilow Cancer Hospital

Cancer cells are characterized by altered metabolism. In this study, the Yale team identified new metabolic vulnerabilities in cancer cells that are based on a loss of enzyme diversity. They found that an enzyme called acetyl-CoA-carboxylase-1 (ACC1), is critical for the survival of breast cancer cells. The ACC1 enzyme is the key initial step in fatty acid synthesis. Fatty acids are building blocks of the various types of lipids and fat that are the critical ingredients of cell membranes and play an important role in energy generation in cells. In their analysis, the team showed that blocking ACC1 using PF05175157 can inhibit the growth of breast cancer cells grown in mice and also in a patient-derived cancer models.

"We are currently testing this drug in combination with other approved breast cancer drugs to see if it could improve their activity, with the hope to bring the most promising combinations to the clinic to help patients with breast cancer," added Lajos Pusztai, MD, DPhil, Professor of Medicine (Medical Oncology), Director of Breast Cancer Translational Research at Yale Cancer Center, and senior author of the study.

Funding for the study was provided by a leadership grant from the Susan G. Komen Foundation.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Flavonoid-rich diet slashes type 2 diabetes risk by up to 28%, new study reveals